Standout Papers

Mechanisms linking obesity to insulin resistance and type 2 diabetes 2003 2026 2010 2018 3.8k
  1. Mechanisms linking obesity to insulin resistance and type 2 diabetes (2006)
    Steven E. Kahn, Rebecca L. Hull et al. Nature
  2. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy (2006)
    Steven E. Kahn, Steven M. Haffner et al. New England Journal of Medicine
  3. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes (2003)
    Steven E. Kahn Diabetologia
  4. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex (2003)
    Miriam Cnop, Peter J. Havel et al. Diabetologia
  5. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2013)
    Steven E. Kahn, Mark E. Cooper et al. The Lancet
  6. Quantification of the Relationship Between Insulin Sensitivity and β-Cell Function in Human Subjects: Evidence for a Hyperbolic Function (1993)
    Steven E. Kahn, Ronald L. Prigeon et al. Diabetes
  7. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023)
    A. Michael Lincoff, Kirstine Brown‐Frandsen et al. New England Journal of Medicine
  8. Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity (2004)
    Utpal B. Pajvani, Meredith Hawkins et al. Journal of Biological Chemistry
  9. Intra-Abdominal Fat Is a Major Determinant of the National Cholesterol Education Program Adult Treatment Panel III Criteria for the Metabolic Syndrome (2004)
    Darcy B. Carr, Kristina M. Utzschneider et al. Diabetes
  10. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk (2018)
    Julio Rosenstock, Vlado Perkovic et al. JAMA
  11. The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease (2006)
    Kristina M. Utzschneider, Steven E. Kahn The Journal of Clinical Endocrinology & Metabolism
  12. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes (2003)
    Donna H. Ryan, Mark A. Espeland et al. Controlled Clinical Trials
  13. Prevention of Diabetes in Women with a History of Gestational Diabetes: Effects of Metformin and Lifestyle Interventions (2008)
    Robert E. Ratner, Costas A. Christophi et al. The Journal of Clinical Endocrinology & Metabolism
  14. The Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes (2001)
    Steven E. Kahn The Journal of Clinical Endocrinology & Metabolism
  15. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes (2019)
    Julio Rosenstock, Steven E. Kahn et al. JAMA
  16. COVID-19, Hyperglycemia, and New-Onset Diabetes (2021)
    Kamlesh Khunti, Stefano Del Prato et al. Diabetes Care
  17. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics (2023)
    Stephen J. Nicholls, Deepak L. Bhatt et al. American Heart Journal
  18. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial (2024)
    Donna H. Ryan, Ildiko Lingvay et al. Nature Medicine
  19. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials (2024)
    Mikhail Kosiborod, John Deanfield et al. The Lancet
  20. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial (2024)
    Helen M. Colhoun, Ildiko Lingvay et al. Nature Medicine
  21. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial (2024)
    John Deanfield, Subodh Verma et al. The Lancet

Immediate Impact

2 by Nobel laureates 16 from Science/Nature 120 standout
Sub-graph 1 of 19

Citing Papers

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 Standout
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
2025 Standout
20 intermediate papers

Works of Steven E. Kahn being referenced

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design
2020
and 16 more

Author Peers

Author Last Decade Papers Cites
Steven E. Kahn 20367 12627 12423 13019 467 45.2k
Richard N. Bergman 15615 8987 10689 12034 622 41.1k
Ele Ferrannini 28308 13056 14917 11541 523 50.0k
Ralph A. DeFronzo 23648 11716 20450 17277 411 50.5k
Markku Laakso 22794 11434 15999 13178 667 56.6k
Ralph A. DeFronzo 18905 7986 13264 11642 282 37.6k
Gerald M. Reaven 29768 10168 13376 18678 663 58.0k
Oluf Pedersen 12555 9236 17825 11409 702 42.4k
Takashi Kadowaki 13603 10229 24742 16009 858 60.5k
Richard E. Pratley 16147 6320 8472 9836 392 34.6k
Steven M. Haffner 32314 10874 10990 11063 517 60.5k

All Works

Loading papers...

Rankless by CCL
2026